Artículos de revistas
Integrated Analysis Of Recombinant Bpv-1 L1 Protein For The Production Of A Bovine Papillomavirus Vlp Vaccine
Registro en:
Vaccine. Elsevier Ltd, v. 35, n. 12, p. 1590 - 1593, 2017.
0264-410X
10.1016/j.vaccine.2017.02.007
2-s2.0-85013127894
Autor
Módolo D.G.
Araldi R.P.
Mazzuchelli-de-Souza J.
Pereira A.
Pimenta D.C.
Zanphorlin L.M.
Beçak W.
Menossi M.
de Cassia Stocco R.
de Carvalho R.F.
Institución
Resumen
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Bovine papillomatosis is an infectious disease that is caused by bovine papillomavirus (BPV), which results in important economic losses. However, no BPV vaccines or effective treatment methods are commercially available to date. Moreover, the absence of papillomavirus replication in vitro makes the use of recombinant protein a promising candidate for vaccine formulations. Hence, we developed an integrated study on the L1 capsid protein of BPV-1, obtained from a bacterial expression system, regarding its purification, biosafety, thermostability and immunogenicity. The results indicated an absence of genotoxicity of the purified recombinant L1 protein, β-sheet prevalence of secondary structure folding, protein stability under high temperatures as well as the presence of capsomeres and VLPs. In addition, preliminary experimental vaccination of calves showed the production of specific antibodies against BPV-1 L1. © 2017 Elsevier Ltd 35 12 1590 1593 CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)